ID   KM12-SM
AC   CVCL_9548
SY   KM12SM; KM12 SM
DR   cancercelllines; CVCL_9548
DR   Cosmic; 1524332
DR   Cosmic; 2820475
DR   GEO; GSM1448188
DR   GEO; GSM2299787
DR   KCLB; 80016
DR   PRIDE; PXD006662
DR   TOKU-E; 3802
DR   Wikidata; Q54900062
RX   PubMed=2846163;
RX   PubMed=10091941;
RX   PubMed=10987313;
RX   PubMed=15170669;
RX   PubMed=25926053;
RX   PubMed=29131639;
CC   Population: Caucasian.
CC   Microsatellite instability: Instable (MSI) (PubMed=25926053).
CC   Sequence variation: Gene fusion; HGNC; 8031; NTRK1 + HGNC; 12012; TPM3; Name(s)=TPM3-NTRK1 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Asn1819fs*7 (c.5454_5455insA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1784Hisfs*7 (c.5350_5351delAA); ClinVar=VCV000037959; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129Ter (c.385G>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val73Trpfs*50 (c.216delC) (p.P72fs); ClinVar=VCV000428897; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Heterozygous (from parent cell line).
CC   Omics: miRNA expression profiling.
CC   Omics: Nuclear proteome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
ST   Source(s): PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 13,15
ST   D16S539: 11,12
ST   D21S11: 27,34.2
ST   D5S818: 11
ST   D7S820: 8,9
ST   TH01: 9.3
ST   TPOX: 11,12
ST   vWA: 16,17
DI   NCIt; C4910; Colon carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_9547 ! KM12-C
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 22
//
RX   PubMed=2846163;
RA   Morikawa K., Walker S.M., Nakajima M., Pathak S., Jessup J.M.,
RA   Fidler I.J.;
RT   "Influence of organ environment on the growth, selection, and
RT   metastasis of human colon carcinoma cells in nude mice.";
RL   Cancer Res. 48:6863-6871(1988).
//
RX   PubMed=10091941; DOI=10.1023/A:1006537609469;
RA   Nakayama Y., Okazaki K., Shibao K., Sako T., Hirata K., Nagata N.,
RA   Kuwano M., Itoh H.;
RT   "Alterative expression of the collagenase and adhesion molecules in
RT   the highly metastatic clones of human colonic cancer cell lines.";
RL   Clin. Exp. Metastasis 16:461-469(1998).
//
RX   PubMed=10987313;
RA   Yano S., Shinohara H., Herbst R.S., Kuniyasu H., Bucana C.D.,
RA   Ellis L.M., Davis D.W., McConkey D.J., Fidler I.J.;
RT   "Expression of vascular endothelial growth factor is necessary but not
RT   sufficient for production and growth of brain metastasis.";
RL   Cancer Res. 60:4959-4967(2000).
//
RX   PubMed=15170669; DOI=10.1002/ijc.20195;
RA   Camps J., Morales C., Prat E., Ribas M., Capella G., Egozcue J.,
RA   Peinado M.A., Miro R.;
RT   "Genetic evolution in colon cancer KM12 cells and metastatic
RT   derivates.";
RL   Int. J. Cancer 110:869-874(2004).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=29131639; DOI=10.1021/acs.jproteome.7b00548;
RA   Torres S., Garcia-Palmero I., Marin-Vicente C., Bartolome R.A.,
RA   Calvino E., Fernandez-Acenero M.J., Casal J.I.;
RT   "Proteomic characterization of transcription and splicing factors
RT   associated with a metastatic phenotype in colorectal cancer.";
RL   J. Proteome Res. 17:252-264(2018).
//